Log in to search using one of your social media accounts:

 

Brain cancer research to receive £45m funding
Jeremy Hunt has announced that an estimated £20m in funding will be invested in brain cancer research through the National Institute for Health Research (NIHR) over the next five years. (Source: NHS Networks)
Source: NHS Networks - February 23, 2018 Category: UK Health Source Type: news

Woman becomes sister ’s surrogate after cancer diagnosis 
Erin Silverman, 35, of Potomac, Maryland, became a surrogate after her sister, Randi Fishman, 34, was diagnosed with breast cancer. Erin gave birth to her sister's baby in December. (Source: the Mail online | Health)
Source: the Mail online | Health - February 22, 2018 Category: Consumer Health News Source Type: news

'Mini-tumours' created to battle cancer
The lab-grown versions made from a patient's cancer can predict whether drugs will actually work. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 22, 2018 Category: Consumer Health News Source Type: news

Mini-tumours' created to battle cancer
The lab-grown versions made from a patient's cancer can predict whether drugs will actually work. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 22, 2018 Category: Consumer Health News Source Type: news

Fathers Can Pass Ovarian Cancer Risk To Their Daughters
BOSTON (CBS) – A new study finds that a higher risk of ovarian cancer can be passed from father to daughter. Researchers at the Roswell Park Cancer Institute in Buffalo, NY looked at data from the Familial Ovarian Cancer Registry and discovered a genetic mutation passed from a father to his daughter on the X-chromosome that puts her at higher risk for ovarian cancer. The research team is looking for what the Ovarian Cancer gene looks like. (WBZ-TV) When we think of hereditary ovarian cancer, we often think of the BRCA genes that raise the risk of both ovarian cancer and breast cancer in first degree female relatives,...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - February 22, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Seen On WBZ-TV Syndicated Local Cancer Risk Dr. Mallika Marshall Genes ovarian cancer Source Type: news

Merck to Buy Australian Viral Immuno-oncology Firm for $394 Million Merck to Buy Australian Viral Immuno-oncology Firm for $394 Million
U.S. drugmaker Merck& Co, already one of the leaders in the hot area of cancer immunotherapy, said on Wednesday it had agreed to buy Viralytics for 502 million Australian dollars ($394 million) to expand its pipeline in the sector.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 22, 2018 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news

Some Outcomes Not Necessarily Better With Robotic Prostate Surgery Some Outcomes Not Necessarily Better With Robotic Prostate Surgery
Men with prostate cancer who get the gland removed may be just as likely to suffer erectile dysfunction and urinary incontinence with robotic surgery as with other operations, a UK study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

GenX chemical has contaminated the water in North Carolina, residents troubled by lack of information
(Natural News) Like an unfolding nightmare, the area contaminated by cancer-causing GenX continues to grow. The Fayetteville Observer reported that North Carolina officials have once more broadened the area in Bladen County where ground water is at risk. The N.C. Department of Environmental Quality (DEQ) is investigating wells as far as 2 ½ miles from... (Source: NaturalNews.com)
Source: NaturalNews.com - February 22, 2018 Category: Consumer Health News Source Type: news

FDA clears Endomag ’s Magseed marker for long-term and soft tissue implantation
Surgical guidance company Endomag said today that its Magseed magnetic marker won 510(k) clearance from the FDA, extending the product’s indication to include the marking of soft tissue and long-term implantation. The company’s Magseed device is the only wire-free lesion localization device on the market that can be implanted into any soft tissue with no restrictions on how long the marker can remain in the body, according to Endomag. The Magseed marker is 60% smaller than other non-radioactive localization devices, Endomag explained, and is safe to be imaged with ultrasound, X-ray and MRI, under certain condit...
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Imaging Oncology endomag Source Type: news

Women who lead in life sciences
The Bay Area life sciences scene has some of the most exciting research going on in the world, and much of it is being led by women. In an industry that is overwhelmingly male at an executive level, the Business Times sought to highlight nearly a dozen women who are either leading their company or part of research that could be the wave of the future. From 3D-printed human organs to microbial genes to cancer treatments, these executives and researchers could have a huge impact in the biotech industry.… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 22, 2018 Category: American Health Source Type: news

Radiomics Model Distinguishes Malignant, Benign Lesions on Mammography Radiomics Model Distinguishes Malignant, Benign Lesions on Mammography
A radiomics model using kurtosis MRI reliably distinguishes between malignant and benign lesions identified as suspicious on mammography.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 22, 2018 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Georgia Senate bill would ease limits on Newnan cancer hospital
A new attempt is under way in the General Assembly to ease state regulations on the Cancer Treatment Centers of America hospital in Newnan, Ga., that limit its size and patient mix. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - February 22, 2018 Category: American Health Authors: Dave Williams Source Type: news

Regardless of CV Risks, Cancer History Impacts Mortality
Fibrinogen, von Willebrand factor are potential markers of mortality in cancer survivors (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 22, 2018 Category: Cancer & Oncology Tags: Cardiology, Family Medicine, Gynecology, Internal Medicine, Nursing, Oncology, Pathology, Journal, Source Type: news

Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma Lower-Dose Combo Immunotherapy Promising for Advanced Melanoma
Dr Jeffrey S. Weber reviews data from an open-label phase 1/2 trial assessing the efficacy and safety of combination pembrolizumab and reduced-dose ipilimumab in patients with advanced melanoma.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

' Moving the Needle' in Oncology Workforce Diversity'Moving the Needle' in Oncology Workforce Diversity
Authors of a recent ASCO statement on diversity discuss their experiences and suggestions for improving inclusivity in the oncology workforce.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Practice-Changing Data at 2018 GUCS'Cannot Be Ignored'Practice-Changing Data at 2018 GUCS'Cannot Be Ignored '
A group of practice-changing trials presented at the 2018 Genitourinary Cancers Symposium highlights the growing importance of oncology subspecialty meetings, argues Dr David Graham.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Cancer Immunotherapy: Kinder but Not Harmless Cancer Immunotherapy: Kinder but Not Harmless
An expert in immunotherapy for cancer provides a primer on the side effects of drugs targeting the immune system.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Adjuvant Chemo in Endometrial Cancer: Benefit Only for Some Adjuvant Chemo in Endometrial Cancer: Benefit Only for Some
PORTEC-3 results show that adjuvant chemotherapy improves failure-free survival, although not overall survival, in women with stage III high-risk endometrial cancer, but not in less advanced disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

OncoBreak: Surgical Anxiety; Vets and Tobacco; World-Record Tumor
(MedPage Today) -- News, features, and commentary about cancer-related issues (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - February 22, 2018 Category: American Health Source Type: news

GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
Decipher testing recognized as standard-of-care in management of prostate cancer patients SAN DIEGO, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced tha... Diagnostics, Oncology GenomeDx Biosciences, NCCN, Decipher Prostate, Prostate Cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Heavy Drinking Is the Biggest Risk Factor for Dementia, Study Says
Hot on the heels of headlines linking alcohol consumption with longer life comes new research that casts a much more sobering light on drinking. According to an analysis of more than 1 million people—the largest study of its kind to date—scientists say that heavy alcohol use is the biggest modifiable risk factor for dementia, especially early-onset forms of the disease. The findings, which are published in The Lancet Public Health, came as a shock to the researchers involved. “We hypothesized that alcohol would play some role, but I don’t think anyone expected the size of the effect to be so large,&...
Source: TIME: Health - February 22, 2018 Category: Consumer Health News Authors: Amanda MacMillan Tags: Uncategorized healthytime onetime Research Source Type: news

Varian Acquires Evinance Innovation, Inc.
Expands 360 Oncology care management platform with clinical decision support PALO ALTO, Calif., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Varian (NYSE: VAR) today announced it has acquired privately-held Montreal-based Evinance Innovat... Devices, Oncology, Mergers & Acquisitions Varian Medical Systems, Evinance Innovation, 360 Oncology, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Breast Cancer Survivors: Transition to PCP Leads to Savings Breast Cancer Survivors: Transition to PCP Leads to Savings
Transitioning breast cancer survivors from management by an oncologist to PCP was shown to use fewer health system costs and resources.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

3D tracking of cancers is paving the way for treatments
Researchers from  The Martin Luther University of Halle-Wittenberg in Germany found that producing high-resolution maps could avoid the need for computer programmes that assess tumours. (Source: the Mail online | Health)
Source: the Mail online | Health - February 22, 2018 Category: Consumer Health News Source Type: news

Oncologist Awarded $13 Million in Gender Discrimination Lawsuit Oncologist Awarded $13 Million in Gender Discrimination Lawsuit
After working at UCLA for 25 years and heading up the lymphoma program, Lauren Pinter-Brown, MD, claimed she experienced gender discrimination and then retaliation for complaining about it.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

East Bay gene editing company snags Gilead deal worth up to $3.2 billion
Sangamo Therapeutics Inc.'s gene-editing technology is playing second fiddle to CRISPR no longer. The Richmond-based company (NASDAQ: SGMO) Thursday disclosed a deal with Kite, a subsidiary of Foster City-based Gilead Sciences Inc. (NASDAQ: GILD), to develop next-generation cell therapies in cancer. It will receive $150 million upfront but could receive $3 billion more over the course of the c ollaboration by hitting a series of milestones. The deal is a huge win for Sangamo, whose zinc finger nucleases… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 22, 2018 Category: Biotechnology Authors: Ron Leuty Source Type: news

How artificial intelligence is transforming medicine
Artificial intelligence is part of the new frontier in medicine. In our Grand Round series, Dr. David Agus, who directs research on AI at the University of Southern California and heads USC Norris Westside Cancer Center, joins "CBS This Morning" to discuss how AI is transforming medicine and the risks it poses to patient privacy. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - February 22, 2018 Category: Consumer Health News Source Type: news

Skin cancer WARNING: ‘Staggering’ rise in cases - signs that you should see a GP
CANCER symptoms usually include a change to the body ’s normal processes. Skin cancer cases continue to rise in the UK, especially in men. These are the early signs and symptoms to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - February 22, 2018 Category: Consumer Health News Source Type: news

Tumor Organoids Predict How Well Patients Respond to Cancer Drugs
Testing treatments on mini tumors may save time in identifying which therapies work best, a new study shows. (Source: The Scientist)
Source: The Scientist - February 22, 2018 Category: Science Tags: Daily News,News & Opinion Source Type: news

Novocure misses Q4 EPS by a penny, tops sales estimates
Shares in Novocure (NSDQ:NVCR) rose slightly today in premarket activity after the medical device maker met sales expectations, but missed earnings estimates on Wall Street with its fourth quarter and full-year financial results. The St. Helier, N.J.-based company reeled in losses this quarter, posting -$10.9 million on sales of $53.7 million for the 3 months ended Dec. 31, for sales growth of 78% compared with the same period last year. Get the full story at our sister site, Drug Delivery Business News. The post Novocure misses Q4 EPS by a penny, tops sales estimates appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 22, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations MassDevice Earnings Roundup Oncology Pharmaceuticals Wall Street Beat NovoCure Source Type: news

QOL Boost Seen From Early, Systematic Palliative Care in Patients With Advanced Solid Tumors
In a Belgian study, integration of palliative care as part of cancer care increased the quality of life of patients with advanced malignant solid tumors. (Source: CancerNetwork)
Source: CancerNetwork - February 22, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Palliative and Supportive Care Source Type: news

Sangamo in $3 billion gene-editing deal with Gilead
(Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Kite, a Gilead Company, And Sangamo Therapeutics Announce Collaboration To Develop Next-Generation Engineered Cell Therapies For The Treatment Of Cancer
Kite to Receive Exclusive License to Leverage Sangamo's Gene Editing Technology in Allogeneic and Autologous Cell Therapy Programs in Oncology SANTA MONICA, Calif. and RICHMOND, Calif., Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- Kite, a... Biopharmaceuticals, Oncology, Licensing Sangamo Therapeutics, Kite, Gilead, zinc finger nuclease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 22, 2018 Category: Pharmaceuticals Source Type: news

Gilead signs $3 billion licensing deal for Sangamo's gene-editing platform
(Reuters) - Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday. (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Sudan:Breast Cancer International Conference to Kick Off in Khartoum Friday
[SNA] Khartoum -The Breast Cancer International Conference will take place in in the Friendship Hall in Khartoum Friday. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 22, 2018 Category: African Health Source Type: news

Novel Tumor-Agnostic Agent: 80% RR, but Target Is Rare Novel Tumor-Agnostic Agent: 80% RR, but Target Is Rare
Oral larotrectinib is highly effective in up to 80% of metastatic solid tumors with a TRK fusion, regardless of patient age or tumor type, but these TRK fusions are rare.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Monsanto attacks the IARC for labeling glyphosate a probable carcinogen – using the U.S. government as a weapon
(Natural News) U.S. Right to Know recently reported that even though 39 percent of all Americans will one day be diagnosed with cancer, resulting in hundreds of thousands of deaths, government representatives are going out of their way to protect the manufacturers of a known cancer-causer: The glyphosate produced by agri-giant Monsanto. When the World... (Source: NaturalNews.com)
Source: NaturalNews.com - February 22, 2018 Category: Consumer Health News Source Type: news

Breast cancer symptoms: Men can test for a cancerous lump using these eight steps
BREAST cancer is usually associated with women, but in rare cases, men can get it too. So how can men test for a cancerous lump? Look out for these signs and symptoms and follow these eight steps. (Source: Daily Express - Health)
Source: Daily Express - Health - February 22, 2018 Category: Consumer Health News Source Type: news

iKnowMed Ranked Number One Oncology Electronic Health Record by Black Book Research for Seventh Consecutive Year
The Woodlands, Texas (February 22, 2018) — For the seventh consecutive year, iKnowMedSM electronic health record (EHR) has been named the top-ranked EHR platform for oncologists and hematologists by Black BookTM Research, an unbiased industry-leading source for polling, surveys and market research. (Source: McKesson News)
Source: McKesson News - February 22, 2018 Category: Information Technology Source Type: news

Medical News Today: This specialized gel could improve cancer therapy
Researchers are testing a promising new gel-like medium capable of delivering a combination of therapeutic agents directly to the sites of primary tumors. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 22, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

CD19 Antibody Targeting With MOR208 Is Active in DLBCL
Single-agent MOR208 showed promising activity with long-lasting responses in aggressive and indolent NHL subtypes, including in rituximab-refractory disease. (Source: CancerNetwork)
Source: CancerNetwork - February 22, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Diffuse Large B-Cell Lymphoma Follicular Lymphoma Source Type: news

Ask How Does Breast Cancer Start
How Does Breast Cancer Start? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 22, 2018 Category: General Medicine Source Type: news

New Technology Alone Won ’t Halt Aflatoxin Menace, Experts Warn
Laboratory Technician Herbert Mtopa collects biological samples at a clinic in Zimbabwe's Shamva District under a CultiAF project to assess exposure of women and children to aflatoxins. Credit: Busani Bafana/IPSBy Miriam GathigahNAIROBI, Kenya, Feb 22 2018 (IPS)In the absence of concerted efforts to raise awareness on the dangers of aflatoxin to humans and domestic animals, advances in technology for early detection of aflatoxin in cereals and seeds such as maize will come to naught, experts warn.The first rapid aflatoxin testing kit is in the market for less than two dollars, even as some farmers unwittingly employ life-t...
Source: IPS Inter Press Service - Health - February 22, 2018 Category: International Medicine & Public Health Authors: Miriam Gathigah Tags: Africa Featured Food & Agriculture Headlines Health Projects TerraViva United Nations aflatoxin Food and Agriculture Organization of the United Nations (FAO) Improving the lives of rural populations: better nutrition & agriculture produc Source Type: news

Impact of 70-Gene Signature Use on Chemo Decisions in BC Impact of 70-Gene Signature Use on Chemo Decisions in BC
Do results of gene-expression profiles change whether patients with ER-positive breast cancer receive adjuvant chemotherapy?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

An under-the-radar immune cell shows potential in fight against cancer
(University of British Columbia) One of the rarest of immune cells, Type-2 innate lympoid cells might be a potent weapon in slowing the spread of cancer to other parts of the body. Though known primarily for their role in causing asthma, University of British Columbia scientists found that implanted cancers metastasize much more easily in mice lacking ILC2 cells. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2018 Category: Cancer & Oncology Source Type: news

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells
(University of California - Riverside) A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases. Until now, paclitaxel has only been used to target rapidly dividing cancer cells. The team was successful in getting the drug to piggyback on 123B9, an agent they devised to target an oncogene called EphA2. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2018 Category: Cancer & Oncology Source Type: news

UT Dallas scientists isolate cancer stem cells using novel method
(University of Texas at Dallas) Researchers at The University of Texas at Dallas have devised a new technique to isolate aggressive cells thought to form the root of many hard-to-treat metastasized cancers -- a significant step toward developing new drugs that might target these cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2018 Category: International Medicine & Public Health Source Type: news

Research to uncover factors behind bladder cancer progression receives ACS grant
(Penn State) To find new therapies for aggressive bladder cancer, researchers must first uncover what drives each subtype at the molecular level. That's why the American Cancer Society has awarded a grant to study bladder cancer development to David DeGraff, assistant professor of pathology, surgery and biochemistry and molecular biology, and a member of Penn State Cancer Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2018 Category: International Medicine & Public Health Source Type: news

Researchers develop new technology platform for cancer immunotherapy
(InSilico Medicine, Inc.) Johns Hopkins scientists invent multifunctional antibody-ligand traps (Y-traps), a new class of cancer immunotherapeutics. They develop Y-traps comprising an antibody targeting an immune checkpoint (CTLA-4 or PD-L1) fused to a TGFβ trap. In humanized mouse models, these Y-traps reverse immune suppression and inhibit growth of tumors that do not respond to current immune checkpoint inhibitors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2018 Category: International Medicine & Public Health Source Type: news

NIST introduces new CHO peptide library
(National Institute of Standards and Technology (NIST)) LinkedIn: Chinese Hamster Ovary cells, known as CHO, play an important role in modern medicine. NIST's new CHO peptide library will enable better production of treatments for psoriasis, cancer, hemophilia and leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2018 Category: International Medicine & Public Health Source Type: news